Generic erosion of Korlym
A lower-priced generic version can shift volume away from branded product and compress average selling price.
- Scope
- Core commercial franchise
- Materiality
- high
Corcept Therapeutics Incorporated
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym for patients with hypercortisolism, also known as Cushing’s syndrome. The company also sells an authorized generic version of Korlym in the United States, which broadened its commercial footprint while pressuring average selling prices. Beyond its commercial franchise, Corcept is building a pipeline of selective cortisol modulators for endocrine, oncologic, metabolic and neurologic disorders, including relacorilant, dazucorilant and other proprietary compounds. Its business model combines specialty drug commercialization, physician-focused sales, specialty pharmacy distribution and ongoing clinical development funded largely by product revenue.
6,0 %
98,3 %
13,1 %
+12,8 %
2.92
2.85
| % | |
|---|---|
| Commercial products | 100% Marketed therapies sold in the U.S. for hypercortisolism, including branded Korlym and its authorized generic. |
| Clinical-stage pipeline | 0% Selective cortisol modulators in development for endocrine, neurologic, metabolic and oncology indications. |
| Patient access services | 0% Specialty pharmacy coordination, co-pay support and charitable assistance programs that support access to therapy. |
Corcept’s direct customers are physicians treating patients with hypercortisolism, since the company’s sales force...
- Physicians treating hypercortisolismprimary
Specialists who prescribe Korlym or the generic version based on clinical need and disease severity.
- Patients with Cushing’s syndromeprimary
Patients with severe hypercortisolism who use the product and often need access support to afford treatment.
- Specialty pharmacies and distributorsprimary
Channel partners that dispense, package and deliver the product and manage logistics.
- Commercial and government payorsprimary
Insurers and public programs that determine reimbursement, rebates and patient affordability.
- Clinical research ecosystemsecondary
CROs, investigators and trial sites that support development of relacorilant, dazucorilant and other candidates.
Corcept’s commercial revenue is concentrated in the United States, where it markets Korlym and the authorized generic...
- •Commercial sales are concentrated in the United States
- •Korlym and the authorized generic are sold in the U.S. only
- •Manufacturing is outsourced to contract manufacturers
- •API supply and tablet bottling are dependent on external vendors
- •Pipeline IP is protected in the U.S. and foreign jurisdictions
- •U.S. reimbursement and FDA policy are the main geographic exposures
Corcept’s strategy is to defend and expand its cortisol-modulation franchise while advancing a broader pipeline of...
01
Defend and expand the commercial hypercortisolism franchiseshort-term
Current revenue funds the business, so Corcept must preserve prescribing, access and channel execution despite generic competition and pricing pressure.
02
Advance the cortisol modulator pipelinemedium-term
New indications are needed to diversify the company beyond a single commercial disease area and create longer-term growth.
03
Improve patient access and treatment persistenceshort-term
Specialty drugs depend on reimbursement, affordability and channel reliability, which directly affect realized revenue.
Corcept is exposed to concentration risk because essentially all commercial revenue comes from one disease area and one...
Mifepristone regulatory and reputational risk
Public and legislative scrutiny of mifepristone, even outside hypercortisolism use, may limit prescribing or access.
- Scope
- Commercial demand
- Materiality
- high
Reimbursement and pricing pressure
Government and commercial payors can reduce net realized price through rebates, coverage limits and formulary controls.
- Scope
- Net product revenue
- Materiality
- high
Vendor and supply-chain dependence
The company relies on third parties for API, tableting, packaging and specialty pharmacy services.
- Scope
- Product availability and continuity
- Materiality
- high
Clinical development uncertainty
Pipeline candidates may fail in trials or not achieve regulatory approval, limiting future growth options.
- Scope
- Pipeline valuation
- Materiality
- medium
Net product revenue reserves
Can materially change quarterly revenue and gross margin
Clinical trial and R&D capitalization policy
Affects operating loss/profit and comparability across periods
Inventory and API reserves
Can affect cost of sales and inventory valuation
Quarterly channel timing
Creates seasonality and period-to-period revenue noise
: 11/08/2026